Precision BioSearch is pleased to announce the celebration of its fifth anniversary, marked by the hosting of a CEO and Investor event taking place on 19th November 2025.

Since its founding in 2020, Precision BioSearch has specialised in supporting early-stage ventures as they navigate the critical challenge of hiring in an increasingly turbulent and competitive market. Founded by seasoned recruiters, Jemma Challinor and Malcolm Silander, and recently strengthened by the addition of the highly experienced Natalie Dosanjh, Precision BioSearch has become a trusted partner and go-to provider in the emerging therapeutics sector. Over the past five years, the firm has achieved strong growth across the UK and Europe, while significantly expanding its transatlantic footprint.

In recognition of the company’s fifth year of trading, Precision BioSearch will celebrate this milestone in parallel with London Life Sciences Week (LLSW), a premier gathering of industry leaders, investors, and innovators. Among the week’s flagship events, BIA, BioCentury, Pioneer, Eli Lilly, BBB, PJT, and Precision BioSearch will co-host the 3rd Biotech CEO & Investor Reception at Victoria House. This distinguished gathering will convene CEOs, investors, and other respected industry figures for an evening of informal networking. 

Event Highlights:

• Exclusive C-level and investor networking reception

• Live performance by a traditional Scottish Ceilidh band

• Special guest opening: a bagpipe performance by a serial biotech entrepreneur

• Live recording of the BioCentury This Week podcast, featuring BioCentury analysts and leading industry figures

Reflecting on the occasion, Jemma Challinor, Co-founder of Precision BioSearch, stated:

“Celebrating our fifth anniversary is a milestone that reflects not just our growth, but the trust and collaboration we’ve built across the life sciences community. It is a privilege to bring our network together during LLSW, allowing entrepreneurs, innovators, and investors to connect as we look ahead with optimism for 2026 and beyond. We’re proud of what we’ve achieved over the past five years and excited to continue supporting early-stage ventures as they shape the future of new medicines.”

With the challenges and opportunities facing the biotech sector today, the importance of cultivating strategic relationships has never been greater. We look forward to celebrating this anniversary alongside our peers, partners, and clients, and to continuing our journey of growth and innovation.

For more information:

3rd Biotech CEO & Investor Reception